Asosiy kontentga oʻtish
Maqola

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David AdamsAssistance Publique – Hôpitaux de ParisAlejandra González‐DuarteNational Institute of Medical Sciences and Nutrition–Salvador Zubiran, Mexico CityWilliam O’RiordanBicêtre HospitalChih‐Chao YangHôpital de la TimoneMitsuharu UedaFrom Assistance Publique–Hôpitaux de Paris (APHP), National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire (CHU) Bicêtre, INSERM Unité 1195, Université Paris-Sud, Le Kremlin-Bicêtre (D.A.), the Department of Neuromuscular Disorders and ALS, Hôpital de la Timone, Marseille (S.A.), and the Department of Neurology, Amyloid Network, CHU Henri Mondor–APHP, Créteil (V.P.-B.) — all in France; the National Institute of Medical Sciences and Nutrition–SalvadorArnt V. KristenHeidelberg UniversityIvailo TournevNational Institute of Emergency Medicine "Pirogov"Hartmut SchmidtFrom Assistance Publique–Hôpitaux de Paris (APHP), National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire (CHU) Bicêtre, INSERM Unité 1195, Université Paris-Sud, Le Kremlin-Bicêtre (D.A.), the Department of Neuromuscular Disorders and ALS, Hôpital de la Timone, Marseille (S.A.), and the Department of Neurology, Amyloid Network, CHU Henri Mondor–APHP, Créteil (V.P.-B.) — all in France; the National Institute of Medical Sciences and Nutrition–SalvadorTeresa CoelhoBicêtre HospitalJohn L. BerkBicêtre HospitalKon-Ping LinBicêtre HospitalGiuseppe VitaAssistance Publique – Hôpitaux de ParisShahram AttarianHôpital de la TimoneViolaine Planté‐BordeneuveAssistance Publique – Hôpitaux de ParisMichelle M. MezeiHôpital de la TimoneJosep M. CampistolBicêtre HospitalJuan BuadesHealth Research Institute of the Balearic IslandsThomas H. BrannaganBicêtre HospitalByoung J. KimSamsung Medical Center, Sungkyunkwan University School of Medicine, BostonJeeyoung OhAssistance Publique – Hôpitaux de ParisYeşim ParmanFrom Assistance Publique–Hôpitaux de Paris (APHP), National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire (CHU) Bicêtre, INSERM Unité 1195, Université Paris-Sud, Le Kremlin-Bicêtre (D.A.), the Department of Neuromuscular Disorders and ALS, Hôpital de la Timone, Marseille (S.A.), and the Department of Neurology, Amyloid Network, CHU Henri Mondor–APHP, Créteil (V.P.-B.) — all in France; the National Institute of Medical Sciences and Nutrition–SalvadorYoshiki SekijimaAssistance Publique – Hôpitaux de ParisPhilip N. HawkinsAssistance Publique – Hôpitaux de ParisScott D. SolomonInsermMichael PolydefkisJohns Hopkins Bayview Medical CenterP. James B. DyckAssistance Publique – Hôpitaux de ParisPritesh J. GandhiBicêtre HospitalSunita GoyalAlnylam Pharmaceuticals, Cambridge, MAJihong ChenFrom Assistance Publique–Hôpitaux de Paris (APHP), National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire (CHU) Bicêtre, INSERM Unité 1195, Université Paris-Sud, Le Kremlin-Bicêtre (D.A.), the Department of Neuromuscular Disorders and ALS, Hôpital de la Timone, Marseille (S.A.), and the Department of Neurology, Amyloid Network, CHU Henri Mondor–APHP, Créteil (V.P.-B.) — all in France; the National Institute of Medical Sciences and Nutrition–SalvadorAndrew StrahsAssistance Publique – Hôpitaux de ParisSaraswathy V. NochurInsermMarianne T. SweetserBicêtre HospitalPushkal GargFrom Assistance Publique–Hôpitaux de Paris (APHP), National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire (CHU) Bicêtre, INSERM Unité 1195, Université Paris-Sud, Le Kremlin-Bicêtre (D.A.), the Department of Neuromuscular Disorders and ALS, Hôpital de la Timone, Marseille (S.A.), and the Department of Neurology, Amyloid Network, CHU Henri Mondor–APHP, Créteil (V.P.-B.) — all in France; the National Institute of Medical Sciences and Nutrition–SalvadorAkshay VaishnawAssistance Publique – Hôpitaux de ParisJared GollobAlnylam Pharmaceuticals, Cambridge, MAOle B. SuhrAssistance Publique – Hôpitaux de Paris
2018en
ABI

Annotatsiya

BACKGROUND: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. METHODS: In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropathy, in a 2:1 ratio, to receive intravenous patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks. The primary end point was the change from baseline in the modified Neuropathy Impairment Score+7 (mNIS+7; range, 0 to 304, with higher scores indicating more impairment) at 18 months. Other assessments included the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire (range, -4 to 136, with higher scores indicating worse quality of life), 10-m walk test (with gait speed measured in meters per second), and modified body-mass index (modified BMI, defined as [weight in kilograms divided by square of height in meters]×albumin level in grams per liter; lower values indicated worse nutritional status). RESULTS: A total of 225 patients underwent randomization (148 to the patisiran group and 77 to the placebo group). The mean (±SD) mNIS+7 at baseline was 80.9±41.5 in the patisiran group and 74.6±37.0 in the placebo group; the least-squares mean (±SE) change from baseline was -6.0±1.7 versus 28.0±2.6 (difference, -34.0 points; P<0.001) at 18 months. The mean (±SD) baseline Norfolk QOL-DN score was 59.6±28.2 in the patisiran group and 55.5±24.3 in the placebo group; the least-squares mean (±SE) change from baseline was -6.7±1.8 versus 14.4±2.7 (difference, -21.1 points; P<0.001) at 18 months. Patisiran also showed an effect on gait speed and modified BMI. At 18 months, the least-squares mean change from baseline in gait speed was 0.08±0.02 m per second with patisiran versus -0.24±0.04 m per second with placebo (difference, 0.31 m per second; P<0.001), and the least-squares mean change from baseline in the modified BMI was -3.7±9.6 versus -119.4±14.5 (difference, 115.7; P<0.001). Approximately 20% of the patients who received patisiran and 10% of those who received placebo had mild or moderate infusion-related reactions; the overall incidence and types of adverse events were similar in the two groups. CONCLUSIONS: In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number, NCT01960348 .).

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba